Evidence map›Paper›PMID 35421298›Full record

ArticleCentral European journal of public health2022

Real-life experience in the effectiveness, impact on quality of life and safety of dupilumab treatment in patients with moderate to severe atopic dermatitis in the Czech Republic.

Milena Tánczosová, Martina Kojanová, Monika Arenbergerová, Petr Arenberger, Tomáš Doležal, Daniela Štrosová, Jorga Fialová, Spyridon Gkalpakiotis

Abstract read
PubMed Publisher
In one paragraph

Article in Central European journal of public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Milena TánczosováDepartment of Dermatovenereology, Charles University, Third Faculty of Medicine and University Hospital of Kralovske Vinohrady, Prague, Czech Republic.
Martina KojanováDepartment of Dermatovenereology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
Monika ArenbergerováDepartment of Dermatovenereology, Charles University, Third Faculty of Medicine and University Hospital of Kralovske Vinohrady, Prague, Czech Republic.
Petr ArenbergerDepartment of Dermatovenereology, Charles University, Third Faculty of Medicine and University Hospital of Kralovske Vinohrady, Prague, Czech Republic.
Tomáš DoležalValue Outcomes, Prague, Czech Republic.
Daniela ŠtrosováValue Outcomes, Prague, Czech Republic.
Jorga FialováDepartment of Dermatovenereology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
Spyridon GkalpakiotisDepartment of Dermatovenereology, Charles University, Third Faculty of Medicine and University Hospital of Kralovske Vinohrady, Prague, Czech Republic.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe aim of the study was to assess the effectiveness and safety of dupilumab therapy in patients with moderate-to-severe atopic dermatitis (AD) in a real-life Czech bicentric cohort.

methodsWe retrospectively analysed 50 patients with moderate-to-severe AD treated with dupilumab in two centres in the Czech Republic. Baseline characteristics, the Eczema Area and Severity Index (EASI) score and Dermatology Life Quality Index (DLQI) were collected at baseline and each 3 following months. The proportion of patients achieving EASI50, EASI75, EASI90 and EASI100 were analysed. Levels of immunoglobulin E (IgE) were collected before and after 6 and 12 months of therapy. Adverse events were recorded as well.

resultsThirty-two men and 18 women with mean body mass index (BMI) of 25.7 were enrolled in our analysis. The mean age of the patients was 37.6 years and the mean time from diagnosis until the initiation of dupilumab therapy was 35.0 years. After 4 months, EASI75 was achieved by 75.7%, out of which 40.5% achieved EASI90 and 10.8% achieved complete clearance. Improvement continued with time, and the proportion of patients with EASI90 increased to 71.4% at the 6th month and at the 12th month of therapy the EASI90 was 65.2%. EASI100 was achieved by 14.3% and 13.0% at the 6th and 12th month, respectively. A marked reduction was observed in the DLQI and also in IgE levels. EASI responses were independent of BMI. No new safety issues were identified. Adverse events were experienced by 44% (22/50) of the patients and they were all mild in intensity. Conjunctivitis and herpes simplex virus infection were the most common adverse events.

conclusionOur results confirmed the effectiveness and safety of dupilumab in a real-life setting in adult patients with moderate-to-severe AD in the Czech Republic. Dupilumab was well-tolerated and resulted in a significant clinical improvement in combination with improvement of quality of life.

Indexed as

Dermatitis, AtopicQuality of LifeAdultAntibodies, Monoclonal, HumanizedCzech RepublicFemaleHumansImmunoglobulin EMaleRetrospective StudiesSeverity of Illness IndexTreatment OutcomeAntibodies, Monoclonal, HumanizeddupilumabImmunoglobulin Eatopic dermatitisbiological treatmentconjunctivitisdupilumabreal-life

Identifiers

PMID35421298

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.